From genome wide association studies there is increasing evidence of an aberrant immune response in IBD. 4 Susceptibility loci involve both the innate and adaptive immune response towards a diminished diversity of commensal microbiota. 5 Description of the numerous mechanisms contributing to this dysimmunity is beyond the scope of this article. Despite evidence of defective mucosal immunity, there is no proof of a systemic immune defect in patients with IBD in the absence of concomitant immunomodulator therapy.
No takes yet. Share an insight, caveat, or question.
Rahier et al. (2014) studied this question.